Timeline
REGN3479
A Regeneron-developed monoclonal antibody targeting Bundibugyo ebolavirus, now in the first authorised Bundibugyo treatment trial alongside MBP134.
1 of 1 entries (1 events, 0 interactions)
Filters
#712 Jun
A Regeneron-developed monoclonal antibody targeting Bundibugyo ebolavirus, now in the first authorised Bundibugyo treatment trial alongside MBP134.
1 of 1 entries (1 events, 0 interactions)